Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Semo, D; Obergassel, J; Dorenkamp, M; Hemling, P; Strutz, J; Hiden, U; Muller, N; Muller, UA; Zulfikar, SA; Godfrey, R; Waltenberger, J.
The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
J CLIN MED. 2023; 12(4): 1356 Doi: 10.3390/jcm12041356 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Hiden Ursula; Strutz Jasmin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Purpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-REG####
Find related publications in this database (Keywords): diabetes mellitus; empagliflozin; SGLT-2; monocytes; endothelial cells; vascular dysfunction; chemotaxis; reactive oxygen species (ROS); glucose transport; VEGFR-2; VEGFR-1